Aminocaproic acid, 5% 100 ml

Aminocaproic acid promotes the process of blood clotting in bleeding associated with increased fibrinolytic activity of blood. By suppressing the action of plasminogen activators and blocking the action of plasmin, it leads to stopping bleeding.

It is also an inhibitor of kinins (biogenic polypeptides formed in the body from α-globulins under the influence of kallikrein).

It has anti-allergic effect, inhibits the formation of antibodies, increases the detoxification function of the liver and reduces capillary permeability.

Pharmacokinetics

The drug is slightly toxic. When taken orally, it is well absorbed, reaching C_max of aminocaproic acid in the blood within 1-2 hours.

In intravenous administration the action of the drug is seen after 15-20 minutes.

The drug is quickly excreted by the kidneys – about 40-60% of the administered amount is excreted unchanged in the urine after 4 hours.

In case of impaired renal excretion, excretion of aminocaproic acid is delayed; as a result, its concentration in the blood rises sharply.

Indications

to stop and prevent bleeding during surgical interventions and various pathological conditions accompanied by increased fibrinolytic activity of blood and tissues;
state of hypo- and afibrinogenemia: during operations on the lungs, heart and blood vessels (extracorporeal circulation), pancreas, thyroid and prostate glands and other organs;
burn disease;
shock;
premature detachment of a normally located placenta;
long-term retention of a dead fetus in the uterus;
complicated abortion;
neonatal melena;
liver diseases;
acute pancreatitis;
diseases of internal organs with hemorrhagic syndrome (gastrointestinal, uterine, nasal, pulmonary bleeding, leukemia, hypoplastic anemia, hemophilia, etc.);
incompatible blood transfusion;
massive transfusions of blood components to prevent secondary hypofibrinogenemia.

Pharmacological effect

Aminocaproic acid promotes the process of blood clotting during bleeding associated with increased fibrinolytic activity of the blood. By stopping the action of plasminogen activators and blocking the action of plasmin, it stops bleeding.

It is also an inhibitor of kinins (biogenic polypeptides formed in the body from α-globulins under the influence of kallikrein).

It has an antiallergic effect, inhibits the formation of antibodies, increases the detoxification function of the liver, and reduces capillary permeability.

Pharmacokinetics

The drug is low toxic. When taken orally, it is well absorbed, reaching Cmax of aminocaproic acid in the blood within 1-2 hours.

When administered intravenously, the effect of the drug appears after 15-20 minutes.

The drug is quickly excreted by the kidneys – approximately 40-60% of the administered amount is excreted unchanged in the urine after 4 hours.

If the excretory function of the kidneys is impaired, the excretion of aminocaproic acid is delayed, as a result of which its concentration in the blood increases sharply.

Special instructions

The drug for intravenous administration is used only in hospital settings!

When using a solution of aminocaproic acid, it is necessary to check the fibrinolytic activity of the blood; intravenous administration of the drug should be carried out under the control of a coagulogram.

During treatment with aminocaproic acid, it is not recommended to eat fatty foods.

Administration of the drug in case of hematuria is not recommended due to the risk of developing acute renal failure.

Active ingredient

Aminocaproic acid

Composition

1 ml of solution for infusion contains:

active ingredient:

aminocaproic acid 50 mg

Contraindications

hypersensitivity to the drug;
increased blood clotting;
tendency to thrombosis and embolism;
renal dysfunction;
cerebrovascular accident;
DIC syndrome.

Side Effects

headache,
dizziness,
tinnitus,
nausea,
diarrhea,
catarrhal symptoms of the upper respiratory tract,
skin rashes,
orthostatic hypotension,
convulsions.

Interaction

Can be combined with the introduction of hydrolysates, glucose solutions (dextrose solutions), anti-shock solutions. In acute fibrinolysis, the administration of aminocaproic acid with a fibrinogen content of 2-4 g (maximum 8 g) must be supplemented with a subsequent infusion.

Antiplatelet reduction with simultaneous use of direct and indirect anticoagulants.

No medications should be added to the aminocaproic acid solution.

Overdose

Increased side effects (dizziness, nausea, diarrhea, catarrh of the upper respiratory tract) and a sharp inhibition of fibrinolysis.

In cases of overdose, plasminogen activators (streptokinase, urokinase or anistreptase) should be urgently administered.

Storage conditions

In a place protected from light, at a temperature of 0–20 °C

Shelf life

2 years

Manufacturer

Kraspharma PJSC, Russia